1 / 4

CDC/AHA Scientific Statement on Inflammatory Markers and Cardiovascular Disease: Recommendations for Population Science

CDC/AHA Scientific Statement on Inflammatory Markers and Cardiovascular Disease: Recommendations for Population Science. Class III (evidence/agreement that the procedure is not useful/effective and may be harmful), Evidence level C (consensus opinion of experts)

MikeCarlo
Download Presentation

CDC/AHA Scientific Statement on Inflammatory Markers and Cardiovascular Disease: Recommendations for Population Science

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CDC/AHA Scientific Statement on Inflammatory Markers and Cardiovascular Disease: Recommendations for Population Science • Class III (evidence/agreement that the procedure is not useful/effective and may be harmful), Evidence level C (consensus opinion of experts) • The entire adult population should not be screened for hs-CRP for purposes of cardiovascular risk assessment Pearson TA et al. Circulation 2003;107:499–511.

  2. CDC/AHA Scientific Statement on Inflammatory Markers and Cardiovascular Disease: Recommendations for Laboratory Testing • Class IIa (in favor of usefulness), Evidence level B (data derived from nonrandomized studies) • 2 measurements, optimally 2 weeks apart, should be averaged, in fasting or nonfasting metabolically stable patients. If hs-CRP >10 mg/L, test should be repeated and patient examined for sources of infection or inflammation • hs-CRP risk categories: • Low: <1 mg/L • Average: 1–3 mg/L • High: >3 mg/L Pearson TA et al. Circulation 2003;107:499–511.

  3. CDC/AHA Scientific Statement on Inflammatory Markers and Cardiovascular Disease: Recommendations for Clinical Practice (I) • Class IIa (in favor of usefulness), Evidence level B (data derived from nonrandomized studies) • In patients at intermediate global risk (10–20%/10 yr), hs-CRP measurement may help direct evaluation and therapy for primary prevention; benefits uncertain. • Patients with persistent unexplained hs-CRP elevation >10 mg/L should be evaluated for noncardiovascular etiologies. • In patients with stable coronary disease or ACS, hs-CRP may be useful as a marker of prognosis for recurrent events; benefits uncertain. Pearson TA et al. Circulation 2003;107:499–511.

  4. CDC/AHA Scientific Statement on Inflammatory Markers and Cardiovascular Disease: Recommendations for Clinical Practice (II) • Class IIb (usefulness less well established), Evidence level B (data derived from nonrandomized studies) • hs-CRP measurement may be used as part of global risk assessment in primary prevention; benefits uncertain. • hs-CRP may improve motivation for lifestyle modification; benefits uncertain. Pearson TA et al. Circulation 2003;107:499–511.

More Related